Author(s)

Yesim Gokce Kutsal, Nurten Eskiyurt, Jale Irdesel, Vesile Sepici, Hatice Ugurlu, Yesim Kirazli, Fusun Ardic, Mirko Korsic, Tonko Vlak, Mane Grlickov, Snezana Markovic Temelkova, Miroslav Lazarov, Nada Pilipovic, Vera Popovic, Aleksandar Dimic, Branka Kovacev, Dorina Ruci, Argjend Tafaj, Elma Kucukalic-Selimovic, Dijana Avdic, Hajrija Seleskovic, Snjezana Pejicic, Bulent Butun, Gulseren Akyuz, Lale Cerrahoglu, Omer Faruk Sendur, Peyman Yalcin, Sema Oncel, Merih Saridogan, Tunay Sarpel, Mehmet Tosun, Kazim Senel, Savas Gursoy, Ferhan Canturk, Huseyin Demir, Blazenka Miskic, Dalibor Krpan, Franjo Skreb, Simeon Grazio, Zeljka Crncevic-Orlic, Fatih Ozdener, Hakan Oncel

Clinic for Orthopaedic Surgery, Clinical Centre Vodnjansk, Skopje, Macedonia.
Clinic of Endocrinology, Diabetes and Metabolic Disorders, Skopje, Macedonia.
Clinic of Rheumatology, Clinical Centre, Skopje, Macedonia.
Clinical Center of Vojvodina, Novi Sad, Serbia.
Clinical Center, Banja Luka, Bosnia and Herzegovina.
Clinical Hospital Centre, Split, Croatia.
Department of PMR, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
Department of PMR, Clinical Hospital Center Rijeka, Rijeka, Croatia.
Department of PMR, Dr. Josip Bencevic General Hospital, Slavonski Brod, Croatia.
Department of PMR, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey.
Department of PMR, Polyclinic for Internal Medicine, Zagreb, Croatia.
Department of PMR, School of Medicine, Adnan Menderes University, Aydin, Turkey.
Department of PMR, School of Medicine, Akdeniz University, Ankara, Turkey.
Department of PMR, School of Medicine, Ankara University, Ankara, Turkey.
Department of PMR, School of Medicine, Ataturk University, Erzurum, Turkey.
Department of PMR, School of Medicine, Celal Bayar University, Manisa, Turkey.
Department of PMR, School of Medicine, Cukurova University, Adana, Turkey.
Department of PMR, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
Department of PMR, School of Medicine, Ege University, Izmir, Turkey.
Department of PMR, School of Medicine, Erciyes University, Kayseri, Turkey.
Department of PMR, School of Medicine, Gazi University, Ankara, Turkey.
Department of PMR, School of Medicine, Gaziantep University, Gaziantep, Turkey.
Department of PMR, School of Medicine, Hacettepe University, Ankara, Turkey.
Department of PMR, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Department of PMR, School of Medicine, Marmara University, Istanbul, Turkey.
Department of PMR, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
Department of PMR, School of Medicine, Pamukkale University, Denizli, Turkey.
Department of PMR, School of Medicine, Selcuk University, Konya, Turkey.
Department of PMR, School of Medicine, Uludag University, Bursa, Turkey.
Department of PMR, University Hospital “Sestre Milosrdnice”, Zagreb, Croatia.
Department of PMR, University Hospital Dubrava, Zagreb, Croatia.
Department of Rheumatology, University Hospital Center “Mother Teresa”, Tirana, Albania.
Institut Za Prevenciju, Lecenje I Rehabilitaciju, Niska Banja, Serbia.
Institute for Nuclear Medicine, Sarajevo, Bosnia and Herzegovina.
Institute of Endocrinology CCS, Belgrade, Serbia.
Institute of Physical Medicine & Rehabilitation, Sarajevo, Bosnia and Herzegovina.
Institute of Rheumatology, Belgrade, Serbia.
Klinicki Bolnicki Centar, Zagreb, Croatia.
Orthopaedic Department, University Hospital Center “Mother Teresa”, Tirana, Albania.
Roche Pharmaceuticals, Istanbul, Turkey.
University Hospital Center of Tuzla, Tuzla, Bosnia and Herzegovina.

A candidate identification questionnaire (CIQ) was tested to determine its predictive value for patient-reported satisfaction in patients switched from once-weekly or once-daily treatment with a bisphosphonate to once-monthly dosing. This was a prospective, open-label, multicenter international study in patients with postmenopausal osteoporosis who had been receiving once-daily or once-weekly alendronate or risendronate for at least 3 months. Patients completed a CIQ, then commenced 150 mg monthly ibandronate for 6 months. Patients completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q^TM) at baseline for 6 months. Scores were converted to composite satisfaction scores (CSS, scale 0-100). Totally 677 patients completed a CIQ, 645 were enrolled in the treatment phase and comprised the intent-to-treat (ITT) population, and 630 completed the study. In the ITT population, 68.1% patients answered “yes” to one or more CIQ questions. OPSAT-Q scores increased for the convenience, quality of life and overall satisfaction domains (p < 0.001). Decreases in scores for the side effects domains were significant (p < 0.001) in the CIQ “yes” group, but not for the degree of bother (decrease in mean of 0.1 points, p = 0.50) or duration (no change, p = 0.84) of non-gastrointestinal side effects. Of 638 patients who completed the preference questionnaire, 93.0% of patients preferred the once-monthly dosing schedule and 563 patients (90.7%) found it more convenient. The most common adverse events were dyspepsia (1.9%), nausea (1.1%), and upper abdominal pain (0.9%). Patients are likely to prefer treatment with monthly ibandronate to a weekly or monthly bisphosphonate irrespective of their stated preference before switching treatment.

Bisphosphonate; Compliance; Ibandronate; Postmenopausal Osteoporosis

Kutsal, Y. , Eskiyurt, N. , Irdesel, J. , Sepici, V. , Ugurlu, H. , Kirazli, Y. , Ardic, F. , Korsic, M. , Vlak, T. , Grlickov, M. , Temelkova, S. , Lazarov, M. , Pilipovic, N. , Popovic, V. , Dimic, A. , Kovacev, B. , Ruci, D. , Tafaj, A. , Kucukalic-Selimovic, E. , Avdic, D. , Seleskovic, H. , Pejicic, S. , Butun, B. , Akyuz, G. , Cerrahoglu, L. , Sendur, O. , Yalcin, P. , Oncel, S. , Saridogan, M. , Sarpel, T. , Tosun, M. , Senel, K. , Gursoy, S. , Canturk, F. , Demir, H. , Miskic, B. , Krpan, D. , Skreb, F. , Grazio, S. , Crncevic-Orlic, Z. , Ozdener, F. and Oncel, H. (2013) A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study. Health, 5, 30-40. doi: 10.4236/health.2013.57A2004.